<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ciprofloxacin (ophthalmic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ciprofloxacin (ophthalmic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ciprofloxacin (ophthalmic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9049" href="/d/html/9049.html" rel="external">see "Ciprofloxacin (ophthalmic): Drug information"</a> and <a class="drug drug_patient" data-topicid="11581" href="/d/html/11581.html" rel="external">see "Ciprofloxacin (ophthalmic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9611239"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ciloxan</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868813"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Ciloxan;</li>
<li>SANDOZ Ciprofloxacin</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10586564"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Ophthalmic</span></li></ul></div>
<div class="block don drugH1Div" id="F53791849"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8007feb9-bef8-4b73-884d-370aa9c949f9">Bacterial conjunctivitis; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bacterial conjunctivitis; treatment:</b> Ophthalmic: Solution: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) every 2 hours while awake for 2 days, then 1 to 2 drops every 4 hours while awake for the next 5 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="96fac9cd-eb5c-4db1-83bb-c18cf7d1661d">Corneal ulcers; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Corneal ulcers; treatment:</b> Ophthalmic: Solution: Instill 2 drops into the conjunctival sac every 15 minutes for the first 6 hours, then 2 drops every 30 minutes for the remainder of the first day; on the second day, instill 2 drops every hour; on the third day and for the duration of therapy, instill 2 drops every 4 hours thereafter for a total of 14 days; treatment may continue longer if re-epithelialization has not occurred.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F9611430"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8007feb9-bef8-4b73-884d-370aa9c949f9">Bacterial conjunctivitis; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bacterial conjunctivitis; treatment:</b> Ophthalmic:</p>
<p style="text-indent:-2em;margin-left:4em;">Solution: Infants, Children, and Adolescents: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) every 2 hours while awake for 2 days, then 1 to 2 drops every 4 hours while awake for the next 5 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Ointment: Children ≥2 years and Adolescents: Apply <sup>1</sup>/<sub>2</sub>-inch ribbon into the conjunctival sac 3 times daily for 2 days, then twice daily for the next 5 days.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Canadian labeling:</i> Children ≥1 year and Adolescents: Apply <sup>1</sup>/<sub>2</sub>-inch ribbon into the conjunctival sac 3 times daily for 2 days, then twice daily for the next 5 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="96fac9cd-eb5c-4db1-83bb-c18cf7d1661d">Corneal ulcers; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Corneal ulcers; treatment:</b> Ophthalmic:</p>
<p style="text-indent:-2em;margin-left:4em;">Solution: Infants, Children, and Adolescents: Instill 2 drops into the conjunctival sac every 15 minutes for the first 6 hours, then 2 drops every 30 minutes for the remainder of the first day; on the second day, instill 2 drops every hour; on the third day and for the duration of therapy, instill 2 drops every 4 hours thereafter for a total of 14 days; treatment may be extended if re-epithelialization has not occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">Ointment [Canadian Product]: Children ≥12 years and Adolescents: Apply <sup>1</sup>/<sub>2</sub>-inch ribbon into the conjunctival sac every 1 to 2 hours around the clock for 2 days, then every 4 hours for up to 12 days; treatment may be extended if re-epithelialization has not occurred.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51084790"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment may not be necessary as systemic absorption is minimal.</p></div>
<div class="block dohp drugH1Div" id="F51084791"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment may not be necessary as systemic absorption is minimal.</p></div>
<div class="block doa drugH1Div" id="F9611431"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9049" href="/d/html/9049.html" rel="external">see "Ciprofloxacin (ophthalmic): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="66667e5a-50c3-4a01-9a02-3f19aeac051d">Bacterial conjunctivitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bacterial conjunctivitis:</b>
<b>Ophthalmic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Solution: Instill 1 to 2 drops into the conjunctival sac every 2 hours while awake for 2 days and 1 to 2 drops every 4 hours while awake for the next 5 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Ointment: Apply a <sup>1</sup>/<sub>2</sub> inch ribbon into the conjunctival sac 3 times/day for the first 2 days, followed by a <sup>1</sup>/<sub>2</sub> inch ribbon applied twice daily for the next 5 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="30641660-f8c5-4e4a-8cfa-9cc557e5d3c2">Corneal ulcer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Corneal ulcer: </b>
<b>Ophthalmic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Solution: Instill 2 drops into affected eye every 15 minutes for the first 6 hours, then 2 drops into the affected eye every 30 minutes for the remainder of the first day. On day 2, instill 2 drops into the affected eye hourly. On days 3 to 14, instill 2 drops into affected eye every 4 hours. Treatment may continue after day 14 if re-epithelialization has not occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">Ointment (off-label): Apply <sup>1</sup>/<sub>2</sub> inch ribbon into the conjunctival sac every 1 to 2 hours around the clock on the first 2 days, then apply <sup>1</sup>/<sub>2</sub> inch ribbon every 4 hours for up to 12 days. Treatment may continue after day 12 if re-epithelialization has not occurred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Can.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Can.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990713"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; however, dosage adjustment may not be necessary as systemic absorption is minimal.</p></div>
<div class="block doha drugH1Div" id="F50988064"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; however, dosage adjustment may not be necessary as systemic absorption is minimal.</p></div>
<div class="block adr drugH1Div" id="F13854753"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Unpleasant taste (following instillation)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctival hyperemia, corneal disease (≤2%; including crystals), crusting of eyelid, eye discomfort (≤2%; including burning sensation of eyes), eye pruritus, foreign body sensation of eye, scaling of eyelid</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local ocular hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, corneal infiltrates, corneal staining, decreased visual acuity, dry eye syndrome, erythema of eyelid, eye irritation, eye pain, eyelid edema, keratitis, keratoconjunctivitis, lacrimation, lid margin hyperemia, ocular edema, ocular epitheliopathy, photophobia, vision loss</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Dermatologic: Acute generalized exanthematous pustulosis (Lo 2019), erythema multiforme (major) (Arnold 2017)</p></div>
<div class="block coi drugH1Div" id="F9611310"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to ciprofloxacin, other quinolones, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F9611311"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Delayed healing: Corneal healing may be delayed.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis (some fatal), have occurred with quinolone therapy (primarily with systemic use). Prompt discontinuation of drug should occur if skin rash or other symptoms arise.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection. If superinfection is suspected, institute appropriate alternative therapy.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Contact lens wearers: Some products contain benzalkonium chloride which may be absorbed by soft contact lenses; contact lenses should not be worn during treatment of ophthalmologic infections.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Ophthalmic use: For ophthalmic use only. Not for subconjunctival  injection or for introduction into the anterior chamber of the eye. To avoid contamination, do not touch tip of container to any surface.</p></div>
<div class="block foc drugH1Div" id="F9611527"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, Ophthalmic, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ciloxan: 0.3% (3.5 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ciloxan: 0.3% (5 mL [DSC]) [contains benzalkonium chloride, edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.3% (2.5 mL, 5 mL, 10 mL)</p></div>
<div class="block geq drugH1Div" id="F9611242"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F9611529"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Ciloxan Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3% (per gram): $84.81</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ciprofloxacin HCl Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3% (per mL): $3.23 - $9.46</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868814"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, Ophthalmic, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ciloxan: 0.3% (3.5 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ciloxan: 0.3% (5 mL, 10 mL) [contains benzalkonium chloride, edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.3% (5 mL)</p></div>
<div class="block admp drugH1Div" id="F52614215"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">For topical ophthalmic use only. Avoid touching the dropper tip to skin, eye, or other surfaces. Contact lenses should be removed prior to administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Ointment: Instill in the lower conjunctival sac.</p>
<p style="text-indent:-2em;margin-left:2em;">Solution: Apply gentle pressure to lacrimal sac during and for 1 to 2 minutes after instillation or instruct patient to gently close eyelid after administration to decrease risk of absorption and systemic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8100087','lexi-content-ref-6704011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8100087','lexi-content-ref-6704011'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F9611462"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;text-align:justify;display:inline">Ophthalmic: For topical ophthalmic use only; avoid touching tip of applicator to eye or other surfaces. Contact lenses should be removed prior to administration.</p></div>
<div class="block sts drugH1Div" id="F9611358"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Store at 2°C to 25°C (36°F to 77°F). Protect solution from light.</p></div>
<div class="block usep drugH1Div" id="F53570082"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of bacterial conjunctivitis due to susceptible organisms (Ointment: FDA approved in ages ≥2 years and adults; Solution: FDA approved in all ages); treatment of corneal ulcers (Solution: FDA approved in all ages).</p></div>
<div class="block mst drugH1Div" id="F3198568"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ciprofloxacin may be confused with cephalexin </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ciloxan may be confused with Cytoxan</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299045"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F9611335"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F9611269"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">When administered orally or IV, ciprofloxacin crosses the placenta (Giamarellou 1989; Ludlam 1997). The amount of ciprofloxacin available systemically following topical application of the ophthalmic drops is significantly less in comparison to oral or IV doses. If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctal occlusion for 3 to 5 minutes after application to decrease potential exposure to the fetus (Samples 1988).</p></div>
<div class="block pha drugH1Div" id="F9611376"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits DNA-gyrase in susceptible organisms; inhibits relaxation of supercoiled DNA and promotes breakage of double-stranded DNA</p></div>
<div class="block phk drugH1Div" id="F9611379"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Absorption: Only small amounts are absorbed systemically after ophthalmic instillation</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961928"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Aprocin | Bactin | Cero | Ciflox | Ciprin | Ciprox</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Biamotil | Ciloxan | Cloridrato de ciprofloxacino | Maxiflox</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Ciloxacin | Ciproval</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ciprofloxacin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Alcon cilox | Ciprodan oftalmico</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Opthaflox</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan | Ciproval | Sophixin ofteno | Sophixin ungena</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Ciprocin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Oftacilox</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan | Ciprocin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adiflox | Cinfax | Ciplox | Ciplox-i | Ciprocent e/e | Ciprocin | Ciprol | Ciprolar | Ciprozen | Joxin | Ultiflox | Zoxan</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Oftacilox</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Ciprocent</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan | Ciprofloxacin | Opthaflox | Sophixin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cilox | Ciloxan</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan | Ciprolin | Ciproval</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Invoflox | Rocip</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Oftacilox</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ceprolen | Ciloxan | Ciprocin | Opticin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan | Ciplox</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ciprofloxacin | Oftocipro</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ciprocin | Cipromax</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Ciprocin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan | Ciproval</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Quinoftal</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Ciloxan</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Ciplox</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29469784">
<a name="29469784"></a>Arnold M, Wilkerson M. A case of erythema multiforme major following administration of ciprofloxacin ophthalmic drops. <i>Dermatol Online J</i>. 2017;23(10):13030/qt49k2k7xt.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-ophthalmic-pediatric-drug-information/abstract-text/29469784/pubmed" id="29469784" target="_blank">29469784</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ciloxan ointment (ciprofloxacin) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; November 2019.</div>
</li>
<li>
<div class="reference">
                  Ciloxan solution (ciprofloxacin) [prescribing information]. Fort Worth, TX: Alcon Laboratories Inc; April 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Can.1">
<a name="Can.1"></a>Ciloxan (ciprofloxacin) [product monograph]. Dorval, Quebec, Canada: Norvartis Pharmaceuticals Canada Inc; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2589353">
<a name="2589353"></a>Giamarellou H, Kolokythas E, Petrikkos G, et al. "Pharmacokinetics of Three Newer Quinolones in Pregnant and Lactating Women," Ciprofloxacin: major advances in intravenous and oral quinolone therapy. Proceedings of a symposium. April 28 to 29, 1989, Naples, Florida.<i> Am J Med</i>. 1989; 87(5A):49S-51S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-ophthalmic-pediatric-drug-information/abstract-text/2589353/pubmed" id="2589353" target="_blank">2589353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31821140">
<a name="31821140"></a>Lo KBU, Azmaiparashvili Z. Desquamating pustular rash. <i>Cleve Clin J Med</i>. 2019;86(12):780-781. doi:10.3949/ccjm.86a.19061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-ophthalmic-pediatric-drug-information/abstract-text/31821140/pubmed" id="31821140" target="_blank">31821140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9120330">
<a name="9120330"></a>Ludlam H, Wreghitt TG, Thornton S. Q fever in pregnancy. <i>J Infect</i>. 1997;34(1):75-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-ophthalmic-pediatric-drug-information/abstract-text/9120330/pubmed" id="9120330" target="_blank">9120330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2903673">
<a name="2903673"></a>Samples JR, Meyer SM. Use of ophthalmic medications in pregnant and nursing women. <i>Am J Ophthalmol</i>. 1988;106(5):616-623.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-ophthalmic-pediatric-drug-information/abstract-text/2903673/pubmed" id="2903673" target="_blank">2903673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8100087">
<a name="8100087"></a>Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. <i>Surv Ophthalmol.</i> 1993;37(6):435-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-ophthalmic-pediatric-drug-information/abstract-text/8100087/pubmed" id="8100087" target="_blank">8100087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6704011">
<a name="6704011"></a>Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. <i>Arch Ophthalmol</i>. 1984 102(4):551-553.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ciprofloxacin-ophthalmic-pediatric-drug-information/abstract-text/6704011/pubmed" id="6704011" target="_blank">6704011</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 15950 Version 252.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
